Product
Natural Killer Cell Therapy
3 clinical trials
14 indications
Indication
Plasma Cell LeukemiaIndication
Multiple MyelomaIndication
Adult T-Cell Leukemia/LymphomaIndication
BCR-ABL1-positiveIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Myelodysplastic SyndromeIndication
Recurrent Acute Myeloid LeukemiaIndication
Chronic Myelogenous LeukemiaIndication
Therapy-Related Acute Myeloid LeukemiaClinical trial
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/LymphomasStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase I/II Clinical Trial of NK Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell TransplantationStatus: Completed, Estimated PCD: 2022-02-28